Neuromuscular Blockade Correlates with Hormones and Body Composition in Acromegaly

Table 1

Clinical characteristics, body composition, and hormone levels of patients with acromegaly and controls.

	Patients with acromegaly (n = 20)	Controls (n = 17)
Male, n (%)	11 (55.00)	5 (29.41)	0.185
Age, years	42.15 ± 9.78	48.18 ± 13.12	0.119
Height, cm	168.75 ± 7.69	164.65 ± 6.88	0.099
Weight, kg	73.60 ± 14.72	67.81 ± 11.64	0.199
Body mass index	25.76 ± 3.62	24.98 ± 3.86	0.583
Hypertension, n (%)	5 (25.00)	3 (17.65)	0.701
Diabetes mellitus, n (%)	4 (20.00)	2 (11.76)	0.667
Lean body mass, kg	56.46 ± 11.59	47.31 ± 7.52	0.007
Total muscle mass, kg	52.86 ± 10.97	44.19 ± 7.12	0.007
Skeletal muscle mass, kg	37.96 ± 8.23	31.58 ± 5.08	0.007
Body fat percentage, %	23.24 ± 5.04	29.86 ± 5.77	0.001
GH nadir, ng/mL	11.69 ± 7.53	NA	NA
Random GH, ng/mL	19.59 ± 16.04	0.37 ± 0.39	<0.001
IGF-1, ng/mL	1005.00 ± 274.77	160.76 ± 66.29	<0.001
GH burden, ngm/mL	1694.72 ± 1977.98	13.58 ± 22.95	0.001
IGF-1 burden, ngm/mL	85427.50 ± 62004.96	7483.82 ± 11191.55	<0.001

GH: growth hormone; IGF-1: insulin-like growth factor 1.